511 related articles for article (PubMed ID: 23420887)
21. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
22. Bromodomain and Extraterminal Inhibition by JQ1 Produces Divergent Transcriptional Regulation of Suppressors of Cytokine Signaling Genes in Adipocytes.
Mota de Sá P; Richard AJ; Stephens JM
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31875887
[TBL] [Abstract][Full Text] [Related]
23. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
25. BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction.
Meng S; Zhang L; Tang Y; Tu Q; Zheng L; Yu L; Murray D; Cheng J; Kim SH; Zhou X; Chen J
J Dent Res; 2014 Jul; 93(7):657-62. PubMed ID: 24799421
[TBL] [Abstract][Full Text] [Related]
26. When are the BET factors the most sensitive to bromodomain inhibitors?
Khochbin S
Transcription; 2013; 4(2):54-7. PubMed ID: 23412362
[TBL] [Abstract][Full Text] [Related]
27. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
28. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
30. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
31. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
Jones Lipinski RA; Stancill JS; Nuñez R; Wynia-Smith SL; Sprague DJ; Nord JA; Bird A; Corbett JA; Smith BC
Am J Physiol Regul Integr Comp Physiol; 2024 Jun; 326(6):R515-R527. PubMed ID: 38618911
[TBL] [Abstract][Full Text] [Related]
32. JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis.
Lee MB; Lee JH; Hong SH; You JS; Nam ST; Kim HW; Park YH; Lee D; Min KY; Park YM; Kim YM; Kim HS; Choi WS
BMB Rep; 2017 Dec; 50(12):640-646. PubMed ID: 29187284
[TBL] [Abstract][Full Text] [Related]
33. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
34. BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.
Deeney JT; Belkina AC; Shirihai OS; Corkey BE; Denis GV
PLoS One; 2016; 11(3):e0151329. PubMed ID: 27008626
[TBL] [Abstract][Full Text] [Related]
35. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
[TBL] [Abstract][Full Text] [Related]
36. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Bevill SM; Olivares-Quintero JF; Sciaky N; Golitz BT; Singh D; Beltran AS; Rashid NU; Stuhlmiller TJ; Hale A; Moorman NJ; Santos CM; Angus SP; Zawistowski JS; Johnson GL
Mol Cancer Res; 2019 Jul; 17(7):1503-1518. PubMed ID: 31000582
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
38. BET protein inhibition regulates cytokine production and promotes neuroprotection after spinal cord injury.
Sánchez-Ventura J; Amo-Aparicio J; Navarro X; Penas C
J Neuroinflammation; 2019 Jun; 16(1):124. PubMed ID: 31186006
[TBL] [Abstract][Full Text] [Related]
39.
Nord JA; Wynia-Smith SL; Gehant AL; Jones Lipinski RA; Naatz A; Rioja I; Prinjha RK; Corbett JA; Smith BC
Front Endocrinol (Lausanne); 2022; 13():923925. PubMed ID: 36176467
[TBL] [Abstract][Full Text] [Related]
40. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]